Pepgen INC 10-K annual reports

PepGen Inc. reports on its 2025 fiscal year, highlighting the advancement of its lead DM1 candidate PGN-EDODM1 into Phase 2 trials, despite an FDA partial clinical hold, and the discontinuation of its DMD program.

PepGen Inc.'s 10-K filing summarizes the company's financial performance for fiscal year 2024 and provides updates on its clinical development programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

PepGen Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted internal controls language from its auditor's report.

PepGen Inc.'s 10-K filing details the company's progress in developing oligonucleotide therapies for severe neuromuscular and neurologic diseases, highlighting clinical trial advancements and financial status.